Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Retroviral vectors containing chimeric promoter/enhancer elements exhibit cell-type-specific gene expression

L A Couture1, C A Mullen, R A Morgan

  • 1National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.

Human Gene Therapy
|June 1, 1994
PubMed
Summary

This study engineered retroviral vectors with different promoter/enhancer elements to optimize gene expression. The Harvey murine sarcoma virus (HaMSV) and SL3-3 retroviral vectors showed cell-type specific activity, guiding gene therapy design.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GAP JUNCTION FUNCTION IS ESSENTIAL FOR SURVIVAL OF ACUTE LYMPHOBLASTIC LEUKEMIA CELLS.

Experimental oncology·2024
Same author

Technical considerations of endovascular management of true visceral artery aneurysms.

CVIR endovascular·2023
Same author

Access to beds for interventional radiology patients: improving patient care.

Clinical radiology·2023
Same author

Developing day-case units: imperative for optimal patient care in interventional radiology.

Clinical radiology·2023
Same author

Adipose tissue dysfunction in obese horses with equine metabolic syndrome.

Equine veterinary journal·2019
Same author

Background characterization of an ultra-low background liquid scintillation counter.

Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2017

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Retroviral Vector Technology

Background:

  • Moloney murine leukemia virus (Mo-MLV) based retroviral vectors are widely used for gene transfer.
  • The U3 promoter/enhancer region of Mo-MLV dictates viral LTR activity and gene expression levels.
  • Optimizing promoter/enhancer elements is crucial for efficient and targeted gene delivery in gene therapy.

Purpose of the Study:

  • To construct and evaluate chimeric long terminal repeat (chLTR) retroviral vectors.
  • To compare the promoter/enhancer strength of Mo-MLV with other murine retroviruses (AKV, HaMSV, MPSV, SL3-3, Xeno).
  • To assess the cell-type specific gene expression driven by different chLTRs for gene therapy applications.

Main Methods:

  • Construction of retroviral vectors with chLTRs replacing the Mo-MLV U3 region.

Related Experiment Videos

  • Transfection of NIH-3T3 and JURKAT cell lines to assay chloramphenicol acetyl transferase (CAT) reporter gene activity.
  • Generation of producer cell lines and transduction of various mouse and human cell lines and primary cells.

    • Main Results:

    • Harvey murine sarcoma virus (HaMSV) chLTR showed highest activity in NIH-3T3 cells, while SL3-3 was most active in JURKAT cells.
    • HaMSV chLTR was slightly more active than MoMLV chLTR in murine cells; MPSV chLTR was most active in human HepG2 and HeLa cells.
    • SL3-3 chLTR demonstrated highest activity in lymphoid cell lines, but MoMLV showed superior activity in primary human umbilical vein endothelial cells.

    Conclusions:

    • Specific promoter/enhancer elements can significantly enhance gene expression in retroviral-mediated gene transfer.
    • Cell-type specific promoter selection is critical for optimizing gene therapy outcomes.
    • These findings provide valuable insights for designing efficient human gene therapy strategies.